{ "category_counts": { "Analgesia/Addiction": 131, "Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy": 2, "Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy": 8, "Analgesia/Addiction; Neurology; Other": 8, "Analgesia/Addiction; Pediatric": 24, "Anesthesia": 225, "Anesthesia; Neurology": 30, "Anesthesia; Neurology; Pediatric": 18, "Anesthesia; Pediatric": 69, "Anti-Infective": 84, "Anti-Infective; Dermatology": 3, "Anti-Infective; Ophthalmology": 1, "Anti-Infective; Other": 4, "Anti-Infective; Other; Rheumatology": 1, "Anti-Infective; Pediatric": 6, "Antiviral": 15, "Antiviral; Neurology": 5, "Cardiovascular": 202, "Cardiovascular; Endocrinology/Metabolism": 3, "Cardiovascular; Pediatric; Renal": 11, "Dermatology": 6, "Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology": 16, "Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Pulmonary/Allergy; Renal; Rheumatology": 1, "Dermatology; Other": 1, "Endocrinology/Metabolism": 63, "Endocrinology/Metabolism; Gastroenterology": 20, "Endocrinology/Metabolism; Gastroenterology; Other; Pediatric": 53, "Endocrinology/Metabolism; Gastroenterology; Pediatric": 24, "Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition": 9, "Gastroenterology": 31, "Gastroenterology; Neurology; Other": 1, "Gastroenterology; Other": 2, "Gastroenterology; Other; Pediatric": 9, "Gastroenterology; Other; Renal": 5, "Hematology": 24, "Hematology; Oncology; Pediatric": 2, "Medical Imaging": 3, "Neurology": 52, "Neurology; Other": 5, "Neurology; Pediatric; Psychiatry": 40, "Neurology; Psychiatry": 4, "Oncology": 73, "Oncology; Other": 1, "Oncology; Renal; Rheumatology": 4, "Ophthalmology": 8, "Other": 20, "Pediatric; Pulmonary/Allergy": 2, "Psychiatry": 245, "Pulmonary/Allergy": 12, "Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology": 7, "Pulmonary/Allergy; Pediatric": 1, "Renal": 13, "Reproductive": 5, "Rheumatology": 38, "Rheumatology; Oncology": 14, "Total Parenteral Nutrition": 3, "Transplant": 11, "Urology": 5 }, "changed": [], "diff_counts": { "changed": 0, "new": 0, "removed": 0, "status_changed": 0 }, "fetched_at": "2026-04-26T00:12:38+00:00", "new": [], "removed": [], "source_url": "https://api.fda.gov/drug/shortages.json", "status_changed": [], "status_counts": { "Current": 1147, "Resolved": 29, "To Be Discontinued": 507 }, "top_drugs": [ { "categories": [ "Oncology" ], "companies": [ "Accord Healthcare Inc.", "Eugia US LLC", "Fresenius Kabi USA, LLC", "Gland Pharma Limited", "Hospira, Inc., a Pfizer Company", "Ingenus Pharmaceuticals LLC", "Teva Pharmaceuticals USA, Inc.", "Teyro Labs" ], "company_count": 8, "generic_name": "Carboplatin Injection", "latest_update": "2026-04-24", "priority": "high", "record_count": 29, "score": 80, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Accord+Healthcare+Inc.%22+AND+package_ndc%3A%2216729-295-33%22", "status_counts": { "Current": 27, "To Be Discontinued": 2 }, "top_reasons": [ { "count": 9, "reason": "Demand increase for the drug" }, { "count": 8, "reason": "reason not specified" }, { "count": 7, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 2, "reason": "Other" }, { "count": 2, "reason": "Requirements related to complying with good manufacturing practices" } ] }, { "categories": [ "Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology" ], "companies": [ "Eugia US LLC", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Mylan Institutional, a Viatris Company", "Somerset Therapeutics, LLC" ], "company_count": 5, "generic_name": "Dexamethasone Sodium Phosphate Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 16, "score": 80, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexamethasone+Sodium+Phosphate+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-165-30%22", "status_counts": { "Current": 16 }, "top_reasons": [ { "count": 13, "reason": "reason not specified" }, { "count": 3, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Rheumatology; Oncology" ], "companies": [ "Accord Healthcare Inc.", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Teva Pharmaceuticals USA, Inc." ], "company_count": 5, "generic_name": "Methotrexate Sodium Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 14, "score": 80, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Methotrexate+Sodium+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-124-40%22", "status_counts": { "Current": 14 }, "top_reasons": [ { "count": 10, "reason": "reason not specified" }, { "count": 2, "reason": "Other" }, { "count": 1, "reason": "Shortage of an active ingredient" }, { "count": 1, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Analgesia/Addiction; Pediatric", "Anesthesia", "Anesthesia; Pediatric", "Cardiovascular" ], "companies": [ "Amphastar Pharmaceuticals, Inc.", "B. Braun Medical Inc.", "Baxter Healthcare", "Eugia US LLC", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Huons Co., Ltd. (South Korea)", "Sintetica US", "Spectra Medical Devices, LLC" ], "company_count": 10, "generic_name": "Lidocaine Hydrochloride Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 70, "score": 78, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-486-27%22", "status_counts": { "Current": 68, "To Be Discontinued": 2 }, "top_reasons": [ { "count": 55, "reason": "reason not specified" }, { "count": 10, "reason": "Demand increase for the drug" }, { "count": 3, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 2, "reason": "Other" } ] }, { "categories": [ "Anesthesia" ], "companies": [ "Accord Healthcare Inc.", "Amneal Pharmaceuticals", "Baxter Healthcare", "Eugia US LLC", "Fresenius Kabi USA, LLC", "Gland Pharma Limited", "HQ Specialty Pharma", "Hikma Pharmaceuticals USA, Inc.", "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "Meitheal Pharmaceuticals, Inc.", "Mylan Institutional, a Viatris Company", "Par Health, USA LLC" ], "company_count": 14, "generic_name": "Dexmedetomidine Hydrochloride Injection", "latest_update": "2026-04-24", "priority": "high", "record_count": 53, "score": 78, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexmedetomidine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-671-50%22", "status_counts": { "Current": 52, "To Be Discontinued": 1 }, "top_reasons": [ { "count": 44, "reason": "reason not specified" }, { "count": 3, "reason": "Other" }, { "count": 2, "reason": "Delay in shipping of the drug" }, { "count": 2, "reason": "Demand increase for the drug" }, { "count": 2, "reason": "Discontinuation of the manufacture of the drug" } ] }, { "categories": [ "Anesthesia" ], "companies": [ "Caplin Steriles, Ltd.", "Eugia US LLC", "Fresenius Kabi USA, LLC", "InfoRLife SA", "Somerset Therapeutics, LLC" ], "company_count": 5, "generic_name": "Ropivacaine Hydrochloride Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 46, "score": 78, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Ropivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-288-11%22", "status_counts": { "Current": 46 }, "top_reasons": [ { "count": 32, "reason": "reason not specified" }, { "count": 5, "reason": "Demand increase for the drug" }, { "count": 5, "reason": "Other" }, { "count": 4, "reason": "Delay in shipping of the drug" } ] }, { "categories": [ "Anesthesia" ], "companies": [ "Eugia US LLC", "Fresenius Kabi USA, LLC", "Hospira, Inc., a Pfizer Company", "Huons Co., Ltd", "Kindos Pharmaceuticals Co. Ltd.", "Somerset Therapeutics, LLC" ], "company_count": 6, "generic_name": "Bupivacaine Hydrochloride Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 42, "score": 78, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bupivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Kindos+Pharmaceuticals+Co.+Ltd.%22+AND+package_ndc%3A%2271288-723-52%22", "status_counts": { "Current": 42 }, "top_reasons": [ { "count": 36, "reason": "reason not specified" }, { "count": 3, "reason": "Other" }, { "count": 2, "reason": "Demand increase for the drug" }, { "count": 1, "reason": "Delay in shipping of the drug" } ] }, { "categories": [ "Anesthesia; Neurology" ], "companies": [ "Avet Pharmaceuticals, Inc.", "Fresenius Kabi USA, LLC", "Gland Pharma Limited", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "WG Critical Care" ], "company_count": 6, "generic_name": "Midazolam Hydrochloride Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 30, "score": 78, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Midazolam+Hydrochloride+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2270860-601-05%22", "status_counts": { "Current": 30 }, "top_reasons": [ { "count": 14, "reason": "reason not specified" }, { "count": 8, "reason": "Demand increase for the drug" }, { "count": 7, "reason": "Other" }, { "count": 1, "reason": "Delay in shipping of the drug" } ] }, { "categories": [ "Anesthesia" ], "companies": [ "Baxter Healthcare", "Eugia US LLC", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Meitheal Pharmaceuticals, Inc.", "Mylan Institutional, a Viatris Company", "Piramal Critical Care Inc.", "Sagent Pharmaceuticals", "Sandoz Inc.", "XGen Pharmaceuticals DJB, Inc." ], "company_count": 11, "generic_name": "Rocuronium Bromide Injection", "latest_update": "2026-04-24", "priority": "high", "record_count": 26, "score": 78, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rocuronium+Bromide+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-1403-10%22", "status_counts": { "Current": 26 }, "top_reasons": [ { "count": 20, "reason": "reason not specified" }, { "count": 5, "reason": "Demand increase for the drug" }, { "count": 1, "reason": "Delay in shipping of the drug" } ] }, { "categories": [ "Anti-Infective" ], "companies": [ "Baxter Healthcare", "Pfizer Inc.", "Sagent Pharmaceuticals", "Sandoz Inc." ], "company_count": 4, "generic_name": "Clindamycin Phosphate Injection", "latest_update": "2026-04-24", "priority": "high", "record_count": 20, "score": 78, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Clindamycin+Phosphate+Injection%22+AND+company_name%3A%22Sandoz+Inc.%22+AND+package_ndc%3A%220781-3290-09%22", "status_counts": { "Current": 20 }, "top_reasons": [ { "count": 10, "reason": "reason not specified" }, { "count": 6, "reason": "Other" }, { "count": 2, "reason": "Demand increase for the drug" }, { "count": 2, "reason": "Discontinuation of the manufacture of the drug" } ] }, { "categories": [ "Anesthesia; Neurology; Pediatric" ], "companies": [ "Accord Healthcare Inc.", "American Regent, Inc.", "Amphastar Pharmaceuticals, Inc.", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Medefil, Inc." ], "company_count": 7, "generic_name": "Atropine Sulfate Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 18, "score": 76, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Atropine+Sulfate+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-4910-34%22", "status_counts": { "Current": 16, "To Be Discontinued": 2 }, "top_reasons": [ { "count": 10, "reason": "reason not specified" }, { "count": 4, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 3, "reason": "Requirements related to complying with good manufacturing practices" }, { "count": 1, "reason": "Other" } ] }, { "categories": [ "Cardiovascular" ], "companies": [ "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "MSN Laboratories Private Limited", "Mullan Pharmaceutical Inc.", "Sagent Pharmaceuticals" ], "company_count": 5, "generic_name": "Bumetanide Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 12, "score": 76, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bumetanide+Injection%22+AND+company_name%3A%22Sagent+Pharmaceuticals%22+AND+package_ndc%3A%2225021-321-10%22", "status_counts": { "Current": 12 }, "top_reasons": [ { "count": 9, "reason": "reason not specified" }, { "count": 3, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Cardiovascular" ], "companies": [ "Accord Healthcare Inc.", "Avet Pharmaceuticals, Inc.", "Baxter Healthcare", "Eugia US LLC", "Fresenius Kabi USA, LLC", "Gland Pharma Limited", "Hospira, Inc., a Pfizer Company", "Meitheal Pharmaceuticals, Inc.", "Sagent Pharmaceuticals" ], "company_count": 9, "generic_name": "Furosemide Injection", "latest_update": "2026-04-24", "priority": "high", "record_count": 33, "score": 74, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Furosemide+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-280-10%22", "status_counts": { "Current": 33 }, "top_reasons": [ { "count": 18, "reason": "reason not specified" }, { "count": 7, "reason": "Other" }, { "count": 3, "reason": "Requirements related to complying with good manufacturing practices" }, { "count": 3, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 2, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Hematology" ], "companies": [ "B. Braun Medical Inc.", "Baxter Healthcare", "Fresenius Kabi USA, LLC", "Hospira, Inc., a Pfizer Company" ], "company_count": 4, "generic_name": "Heparin Sodium Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 10, "score": 74, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Heparin+Sodium+Injection%22+AND+company_name%3A%22Baxter+Healthcare%22+AND+package_ndc%3A%220338-0431-03%22", "status_counts": { "Current": 9, "To Be Discontinued": 1 }, "top_reasons": [ { "count": 5, "reason": "reason not specified" }, { "count": 2, "reason": "Requirements related to complying with good manufacturing practices" }, { "count": 1, "reason": "Shortage of an inactive ingredient component" }, { "count": 1, "reason": "Other" }, { "count": 1, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Oncology" ], "companies": [ "Accord Healthcare Inc.", "Armas Pharmaceuticals Inc", "Bristol Myers Squibb Co.", "Dr. Reddy's Laboratories, Inc.", "Eugia US LLC", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Meitheal Pharmaceuticals, Inc.", "Teva Pharmaceuticals USA, Inc." ], "company_count": 9, "generic_name": "Azacitidine Injection", "latest_update": "2026-04-20", "priority": "high", "record_count": 9, "score": 73, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Azacitidine+Injection%22+AND+company_name%3A%22Meitheal+Pharmaceuticals%2C+Inc.%22+AND+package_ndc%3A%2271288-115-30%22", "status_counts": { "Current": 9 }, "top_reasons": [ { "count": 7, "reason": "reason not specified" }, { "count": 1, "reason": "Other" }, { "count": 1, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Anti-Infective" ], "companies": [ "Epic Pharma, LLC", "Lupin Pharmaceuticals, Inc." ], "company_count": 2, "generic_name": "Rifampin Capsule", "latest_update": "2026-04-20", "priority": "high", "record_count": 9, "score": 73, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rifampin+Capsule%22+AND+company_name%3A%22Lupin+Pharmaceuticals%2C+Inc.%22+AND+package_ndc%3A%2268180-658-06%22", "status_counts": { "Current": 9 }, "top_reasons": [ { "count": 4, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 3, "reason": "Shortage of an active ingredient" }, { "count": 2, "reason": "reason not specified" } ] }, { "categories": [ "Anti-Infective" ], "companies": [ "Fresenius Kabi USA, LLC", "Mylan Institutional, a Viatris Company", "Sanofi-Aventis U.S. LLC" ], "company_count": 3, "generic_name": "Rifampin Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 4, "score": 73, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rifampin+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-351-20%22", "status_counts": { "Current": 3, "To Be Discontinued": 1 }, "top_reasons": [ { "count": 3, "reason": "reason not specified" }, { "count": 1, "reason": "Discontinuation of the manufacture of the drug" } ] }, { "categories": [ "Analgesia/Addiction; Pediatric" ], "companies": [ "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company" ], "company_count": 3, "generic_name": "Fentanyl Citrate Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 19, "score": 72, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Fentanyl+Citrate+Injection%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220641-6029-25%22", "status_counts": { "Current": 19 }, "top_reasons": [ { "count": 8, "reason": "reason not specified" }, { "count": 8, "reason": "Other" }, { "count": 3, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Anti-Infective" ], "companies": [ "Baxter Healthcare", "Gland Pharma Limited", "InfoRLife SA" ], "company_count": 3, "generic_name": "Metronidazole Injection", "latest_update": "2026-04-20", "priority": "high", "record_count": 4, "score": 72, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Metronidazole+Injection%22+AND+company_name%3A%22InfoRLife+SA%22+AND+package_ndc%3A%220409-0152-24%22", "status_counts": { "Current": 4 }, "top_reasons": [ { "count": 2, "reason": "reason not specified" }, { "count": 1, "reason": "Other" }, { "count": 1, "reason": "Shortage of an active ingredient" } ] }, { "categories": [ "Anesthesia" ], "companies": [ "Caplin Steriles, Ltd.", "Eugia US LLC", "Gland Pharma Limited", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Mylan Institutional, a Viatris Company" ], "company_count": 6, "generic_name": "Etomidate Injection", "latest_update": "2026-04-24", "priority": "high", "record_count": 19, "score": 71, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Etomidate+Injection%22+AND+company_name%3A%22Caplin+Steriles%2C+Ltd.%22+AND+package_ndc%3A%2272485-508-10%22", "status_counts": { "Current": 19 }, "top_reasons": [ { "count": 17, "reason": "reason not specified" }, { "count": 2, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Cardiovascular" ], "companies": [ "Aurobindo Pharma USA", "Chartwell Molecular Holdings LLC", "Lupin Pharmaceuticals, Inc.", "Pfizer Inc.", "Solco Healthcare US, LLC" ], "company_count": 5, "generic_name": "Quinapril Hydrochloride Tablet", "latest_update": "2026-04-24", "priority": "high", "record_count": 20, "score": 70, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Quinapril+Hydrochloride+Tablet%22+AND+company_name%3A%22Lupin+Pharmaceuticals%2C+Inc.%22+AND+package_ndc%3A%2268180-556-09%22", "status_counts": { "Current": 16, "To Be Discontinued": 4 }, "top_reasons": [ { "count": 8, "reason": "reason not specified" }, { "count": 4, "reason": "Requirements related to complying with good manufacturing practices" }, { "count": 4, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 4, "reason": "Shortage of an active ingredient" } ] }, { "categories": [ "Endocrinology/Metabolism; Gastroenterology; Pediatric" ], "companies": [ "Amphastar Pharmaceuticals, Inc.", "Exela Pharma Sciences, LLC", "Fresenius Kabi USA, LLC", "Hospira, Inc., a Pfizer Company", "Long Grove Pharmaceuticals LLC" ], "company_count": 5, "generic_name": "Sodium Bicarbonate Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 19, "score": 70, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Sodium+Bicarbonate+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-083-05%22", "status_counts": { "Current": 15, "To Be Discontinued": 4 }, "top_reasons": [ { "count": 12, "reason": "reason not specified" }, { "count": 4, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 3, "reason": "Other" } ] }, { "categories": [ "Endocrinology/Metabolism; Gastroenterology; Pediatric" ], "companies": [ "Amphastar Pharmaceuticals, Inc.", "Hospira, Inc., a Pfizer Company" ], "company_count": 2, "generic_name": "Dextrose Monohydrate 50% Injection", "latest_update": "2026-04-22", "priority": "high", "record_count": 5, "score": 70, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dextrose+Monohydrate+50%25+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-6648-02%22", "status_counts": { "Current": 4, "To Be Discontinued": 1 }, "top_reasons": [ { "count": 3, "reason": "reason not specified" }, { "count": 1, "reason": "Demand increase for the drug" }, { "count": 1, "reason": "Discontinuation of the manufacture of the drug" } ] }, { "categories": [ "Cardiovascular" ], "companies": [ "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc." ], "company_count": 2, "generic_name": "Propranolol Hydrochloride Injection", "latest_update": "2026-04-23", "priority": "high", "record_count": 2, "score": 70, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Propranolol+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-604-01%22", "status_counts": { "Current": 2 }, "top_reasons": [ { "count": 1, "reason": "reason not specified" }, { "count": 1, "reason": "Shortage of an active ingredient" } ] }, { "categories": [ "Endocrinology/Metabolism; Gastroenterology; Other; Pediatric" ], "companies": [ "B. Braun Medical Inc.", "Baxter Healthcare", "Fresenius Kabi USA, LLC", "Otsuka ICU Medical LLC" ], "company_count": 4, "generic_name": "Dextrose Monohydrate 5% Injection", "latest_update": "2026-04-23", "priority": "medium", "record_count": 36, "score": 69, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dextrose+Monohydrate+5%25+Injection%22+AND+company_name%3A%22Baxter+Healthcare%22+AND+package_ndc%3A%220338-0017-03%22", "status_counts": { "Current": 36 }, "top_reasons": [ { "count": 33, "reason": "reason not specified" }, { "count": 3, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Anti-Infective; Pediatric" ], "companies": [ "Hikma Pharmaceuticals USA, Inc.", "SteriMax, Inc." ], "company_count": 2, "generic_name": "Cefotaxime Sodium Powder, for Solution", "latest_update": "2026-03-12", "priority": "medium", "record_count": 6, "score": 68, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Cefotaxime+Sodium+Powder%2C+for+Solution%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220143-9933-25%22", "status_counts": { "Current": 6 }, "top_reasons": [ { "count": 4, "reason": "Demand increase for the drug" }, { "count": 2, "reason": "reason not specified" } ] }, { "categories": [ "Cardiovascular" ], "companies": [ "Aurobindo Pharma USA", "Chartwell Molecular Holdings LLC" ], "company_count": 2, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "latest_update": "2026-04-24", "priority": "medium", "record_count": 6, "score": 67, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Quinapril%2FHydrochlorothiazide+Tablet%22+AND+company_name%3A%22Aurobindo+Pharma+USA%22+AND+package_ndc%3A%2265862-162-90%22", "status_counts": { "Current": 6 }, "top_reasons": [ { "count": 3, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 3, "reason": "reason not specified" } ] }, { "categories": [ "Psychiatry" ], "companies": [ "Alvogen", "Aurobindo Pharma USA", "Elite Laboratories, Inc.", "Epic Pharma, LLC", "Granules Pharmaceuticals Inc.", "Lannett Company, Inc.", "Oryza Pharmaceuticals Inc.", "Sandoz Inc.", "SpecGx LLC", "Sunrise Pharmaceutical, Inc.", "Teva Pharmaceuticals USA, Inc." ], "company_count": 11, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "latest_update": "2026-04-24", "priority": "medium", "record_count": 73, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Amphetamine+Aspartate+Monohydrate%2C+Amphetamine+Sulfate%2C+Dextroamphetamine+Saccharate%2C+Dextroamphetamine+Sulfate+Tablet%22+AND+company_name%3A%22Teva+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220555-0775-02%22", "status_counts": { "Current": 73 }, "top_reasons": [ { "count": 48, "reason": "reason not specified" }, { "count": 18, "reason": "Shortage of an active ingredient" }, { "count": 3, "reason": "Delay in shipping of the drug" }, { "count": 2, "reason": "Other" }, { "count": 2, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Rheumatology" ], "companies": [ "Amneal Pharmaceuticals", "Eugia US LLC", "Par Health, USA LLC", "Pfizer Inc.", "Sagent Pharmaceuticals" ], "company_count": 5, "generic_name": "Methylprednisolone Acetate Injection", "latest_update": "2026-04-23", "priority": "medium", "record_count": 23, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Methylprednisolone+Acetate+Injection%22+AND+company_name%3A%22Amneal+Pharmaceuticals%22+AND+package_ndc%3A%2270121-1574-1%22", "status_counts": { "Current": 23 }, "top_reasons": [ { "count": 16, "reason": "reason not specified" }, { "count": 4, "reason": "Demand increase for the drug" }, { "count": 2, "reason": "Other" }, { "count": 1, "reason": "Shortage of an active ingredient" } ] }, { "categories": [ "Anesthesia; Pediatric" ], "companies": [ "Fresenius Kabi USA, LLC", "Hospira, Inc., a Pfizer Company" ], "company_count": 2, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "latest_update": "2026-04-23", "priority": "medium", "record_count": 22, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Epinephrine+Bitartrate%2C+Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-3182-03%22", "status_counts": { "Current": 22 }, "top_reasons": [ { "count": 15, "reason": "reason not specified" }, { "count": 7, "reason": "Other" } ] }, { "categories": [ "Anesthesia" ], "companies": [ "Fresenius Kabi USA, LLC", "Hospira, Inc., a Pfizer Company" ], "company_count": 2, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "latest_update": "2026-04-23", "priority": "medium", "record_count": 20, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bupivacaine+Hydrochloride%2C+Epinephrine+Bitartrate+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-9042-17%22", "status_counts": { "Current": 20 }, "top_reasons": [ { "count": 13, "reason": "reason not specified" }, { "count": 6, "reason": "Other" }, { "count": 1, "reason": "Delay in shipping of the drug" } ] }, { "categories": [ "Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition", "Total Parenteral Nutrition" ], "companies": [ "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Milla Pharmaceuticals" ], "company_count": 4, "generic_name": "Sodium Acetate Injection", "latest_update": "2026-04-23", "priority": "medium", "record_count": 12, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Sodium+Acetate+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-3299-26%22", "status_counts": { "Current": 12 }, "top_reasons": [ { "count": 10, "reason": "reason not specified" }, { "count": 1, "reason": "Demand increase for the drug" }, { "count": 1, "reason": "Other" } ] }, { "categories": [ "Cardiovascular" ], "companies": [ "Baxter Healthcare", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company" ], "company_count": 3, "generic_name": "Dopamine Hydrochloride Injection", "latest_update": "2026-04-22", "priority": "medium", "record_count": 12, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dopamine+Hydrochloride+Injection%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220143-9254-25%22", "status_counts": { "Current": 11, "To Be Discontinued": 1 }, "top_reasons": [ { "count": 9, "reason": "reason not specified" }, { "count": 2, "reason": "Demand increase for the drug" }, { "count": 1, "reason": "Other" } ] }, { "categories": [ "Anti-Infective" ], "companies": [ "Laboratorios Atral", "Pfizer Inc." ], "company_count": 2, "generic_name": "Penicillin G Benzathine Injection", "latest_update": "2026-04-22", "priority": "medium", "record_count": 4, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Penicillin+G+Benzathine+Injection%22+AND+company_name%3A%22Pfizer+Inc.%22+AND+package_ndc%3A%2260793-701-10%22", "status_counts": { "Current": 4 }, "top_reasons": [ { "count": 3, "reason": "Other" }, { "count": 1, "reason": "reason not specified" } ] }, { "categories": [ "Anti-Infective; Ophthalmology" ], "companies": [ "Padagis US LLC" ], "company_count": 1, "generic_name": "Bacitracin Ophthalmic Ointment", "latest_update": "2026-02-04", "priority": "medium", "record_count": 1, "score": 66, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bacitracin+Ophthalmic+Ointment%22+AND+company_name%3A%22Padagis+US+LLC%22+AND+package_ndc%3A%220574-4022-35%22", "status_counts": { "Current": 1 }, "top_reasons": [ { "count": 1, "reason": "Discontinuation of the manufacture of the drug" } ] }, { "categories": [ "Cardiovascular" ], "companies": [ "Hikma Pharmaceuticals USA, Inc." ], "company_count": 1, "generic_name": "Furosemide Oral Solution", "latest_update": "2026-03-31", "priority": "medium", "record_count": 3, "score": 65, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Furosemide+Oral+Solution%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220054-3294-50%22", "status_counts": { "Current": 3 }, "top_reasons": [ { "count": 3, "reason": "Shortage of an inactive ingredient component" } ] }, { "categories": [ "Cardiovascular; Pediatric; Renal" ], "companies": [ "Baxter Healthcare", "Hainan Poly Pharm. Co., Ltd.", "Hospira, Inc., a Pfizer Company", "Pfizer Inc." ], "company_count": 4, "generic_name": "Dobutamine Hydrochloride Injection", "latest_update": "2026-04-22", "priority": "medium", "record_count": 11, "score": 64, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dobutamine+Hydrochloride+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-2344-02%22", "status_counts": { "Current": 10, "To Be Discontinued": 1 }, "top_reasons": [ { "count": 7, "reason": "reason not specified" }, { "count": 4, "reason": "Other" } ] }, { "categories": [ "Hematology" ], "companies": [ "Apotex Corp.", "Ferring" ], "company_count": 2, "generic_name": "Desmopressin Acetate Spray", "latest_update": "2026-04-20", "priority": "medium", "record_count": 4, "score": 64, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Desmopressin+Acetate+Spray%22+AND+company_name%3A%22Ferring%22+AND+package_ndc%3A%2269918-501-05%22", "status_counts": { "Current": 4 }, "top_reasons": [ { "count": 3, "reason": "Requirements related to complying with good manufacturing practices" }, { "count": 1, "reason": "reason not specified" } ] }, { "categories": [ "Gastroenterology; Other; Pediatric" ], "companies": [ "B. Braun Medical Inc.", "Baxter Healthcare", "Otsuka ICU Medical LLC" ], "company_count": 3, "generic_name": "Sterile Water Irrigant", "latest_update": "2026-04-20", "priority": "medium", "record_count": 9, "score": 63, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Sterile+Water+Irrigant%22+AND+company_name%3A%22B.+Braun+Medical+Inc.%22+AND+package_ndc%3A%220264-2101-00%22", "status_counts": { "Current": 9 }, "top_reasons": [ { "count": 4, "reason": "Other" }, { "count": 3, "reason": "Discontinuation of the manufacture of the drug" }, { "count": 2, "reason": "reason not specified" } ] }, { "categories": [ "Analgesia/Addiction" ], "companies": [ "Amphastar Pharmaceuticals, Inc.", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Piramal Critical Care Inc." ], "company_count": 5, "generic_name": "Morphine Sulfate Injection", "latest_update": "2026-04-23", "priority": "medium", "record_count": 25, "score": 62, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Morphine+Sulfate+Injection%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220641-6126-25%22", "status_counts": { "Current": 22, "To Be Discontinued": 3 }, "top_reasons": [ { "count": 12, "reason": "reason not specified" }, { "count": 8, "reason": "Other" }, { "count": 4, "reason": "Demand increase for the drug" }, { "count": 1, "reason": "Shortage of an active ingredient" } ] }, { "categories": [ "Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy", "Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy" ], "companies": [ "Hikma Pharmaceuticals USA, Inc.", "XGen Pharmaceuticals DJB, Inc." ], "company_count": 2, "generic_name": "Promethazine Hydrochloride Injection", "latest_update": "2026-04-21", "priority": "medium", "record_count": 10, "score": 62, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Promethazine+Hydrochloride+Injection%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220641-6083-25%22", "status_counts": { "Current": 10 }, "top_reasons": [ { "count": 6, "reason": "reason not specified" }, { "count": 2, "reason": "Demand increase for the drug" }, { "count": 2, "reason": "Other" } ] }, { "categories": [ "Oncology" ], "companies": [ "ESTEVE PHARMACEUTICALS, S.A.", "Teva Pharmaceuticals USA, Inc." ], "company_count": 2, "generic_name": "Streptozocin Powder, For Solution", "latest_update": "2026-04-16", "priority": "medium", "record_count": 2, "score": 61, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Streptozocin+Powder%2C+For+Solution%22+AND+company_name%3A%22ESTEVE+PHARMACEUTICALS%2C+S.A.%22+AND+package_ndc%3A%2268118-100-01%22", "status_counts": { "Current": 2 }, "top_reasons": [ { "count": 1, "reason": "reason not specified" }, { "count": 1, "reason": "Other" } ] }, { "categories": [ "Psychiatry" ], "companies": [ "Alvogen", "Amneal Pharmaceuticals", "Apotex Corp.", "Elite Laboratories, Inc.", "Hikma Pharmaceuticals USA, Inc.", "Lannett Company, Inc.", "Mylan Pharmaceuticals Inc., a Viatris Company", "Rhodes Pharmaceuticals L.P.", "Solco Healthcare US, LLC", "SpecGx LLC", "Sun Pharmaceutical Industries, Inc.", "Takeda Pharmaceuticals USA Inc." ], "company_count": 13, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "latest_update": "2026-04-20", "priority": "medium", "record_count": 90, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lisdexamfetamine+Dimesylate+Capsule%22+AND+company_name%3A%22Solco+Healthcare+US%2C+LLC%22+AND+package_ndc%3A%2243547-606-10%22", "status_counts": { "Current": 90 }, "top_reasons": [ { "count": 54, "reason": "reason not specified" }, { "count": 34, "reason": "Shortage of an active ingredient" }, { "count": 1, "reason": "Other" }, { "count": 1, "reason": "Delay in shipping of the drug" } ] }, { "categories": [ "Psychiatry" ], "companies": [ "Janssen Pharmaceuticals", "Lannett Company, Inc.", "SpecGx LLC", "Sun Pharmaceutical Industries, Inc.", "Teva Pharmaceuticals USA, Inc.", "Trigen Laboratories, LLC", "Vertical Pharmaceuticals, LLC" ], "company_count": 7, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "latest_update": "2026-04-17", "priority": "medium", "record_count": 39, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Methylphenidate+Hydrochloride+Tablet%2C+Extended+Release%22+AND+company_name%3A%22Lannett+Company%2C+Inc.%22+AND+package_ndc%3A%2262175-312-37%22", "status_counts": { "Current": 39 }, "top_reasons": [ { "count": 16, "reason": "reason not specified" }, { "count": 7, "reason": "Demand increase for the drug" }, { "count": 5, "reason": "Other" }, { "count": 4, "reason": "Shortage of an active ingredient" }, { "count": 4, "reason": "Discontinuation of the manufacture of the drug" } ] }, { "categories": [ "Analgesia/Addiction" ], "companies": [ "Alembic Pharmaceuticals", "Baxter Healthcare", "Fresenius Kabi USA, LLC", "Gland Pharma Limited", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company", "Sagent Pharmaceuticals" ], "company_count": 7, "generic_name": "Ketorolac Tromethamine Injection", "latest_update": "2026-04-24", "priority": "medium", "record_count": 25, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Ketorolac+Tromethamine+Injection%22+AND+company_name%3A%22Baxter+Healthcare%22+AND+package_ndc%3A%220338-0072-25%22", "status_counts": { "Current": 25 }, "top_reasons": [ { "count": 12, "reason": "reason not specified" }, { "count": 9, "reason": "Other" }, { "count": 3, "reason": "Delay in shipping of the drug" }, { "count": 1, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Psychiatry" ], "companies": [ "Novadoz Pharmaceuticals LLC", "Sun Pharmaceutical Industries, Inc.", "Takeda Pharmaceuticals USA Inc." ], "company_count": 3, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "latest_update": "2026-04-17", "priority": "medium", "record_count": 18, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lisdexamfetamine+Dimesylate+Tablet%2C+Chewable%22+AND+company_name%3A%22Takeda+Pharmaceuticals+USA+Inc.%22+AND+package_ndc%3A%2259417-115-01%22", "status_counts": { "Current": 18 }, "top_reasons": [ { "count": 12, "reason": "reason not specified" }, { "count": 6, "reason": "Shortage of an active ingredient" } ] }, { "categories": [ "Gastroenterology" ], "companies": [ "B. Braun Medical Inc.", "Baxter Healthcare", "Otsuka ICU Medical LLC" ], "company_count": 3, "generic_name": "Amino Acid Injection", "latest_update": "2026-04-20", "priority": "medium", "record_count": 16, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Amino+Acid+Injection%22+AND+company_name%3A%22B.+Braun+Medical+Inc.%22+AND+package_ndc%3A%220264-4500-00%22", "status_counts": { "Current": 16 }, "top_reasons": [ { "count": 13, "reason": "reason not specified" }, { "count": 2, "reason": "Shortage of an active ingredient" }, { "count": 1, "reason": "Demand increase for the drug" } ] }, { "categories": [ "Neurology" ], "companies": [ "Amphastar Pharmaceuticals, Inc.", "Fresenius Kabi USA, LLC", "Hikma Pharmaceuticals USA, Inc.", "Hospira, Inc., a Pfizer Company" ], "company_count": 4, "generic_name": "Lorazepam Injection", "latest_update": "2026-04-23", "priority": "medium", "record_count": 11, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lorazepam+Injection%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220641-6001-25%22", "status_counts": { "Current": 11 }, "top_reasons": [ { "count": 7, "reason": "Other" }, { "count": 3, "reason": "Demand increase for the drug" }, { "count": 1, "reason": "reason not specified" } ] }, { "categories": [ "Neurology" ], "companies": [ "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)" ], "company_count": 1, "generic_name": "Riluzole Oral Suspension", "latest_update": "2026-04-20", "priority": "medium", "record_count": 4, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Riluzole+Oral+Suspension%22+AND+company_name%3A%22EDW+Pharma%2C+Inc.+%28formerly+Italfarmaco+Pharma%2C+Inc.%29%22+AND+package_ndc%3A%2270726-0306-1%22", "status_counts": { "Current": 4 }, "top_reasons": [ { "count": 3, "reason": "reason not specified" }, { "count": 1, "reason": "Requirements related to complying with good manufacturing practices" } ] }, { "categories": [ "Medical Imaging" ], "companies": [ "Curium US LLC", "Sun Pharmaceutical Industries, Inc." ], "company_count": 2, "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "latest_update": "2026-04-17", "priority": "medium", "record_count": 3, "score": 59, "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Technetium+TC-99M+Pyrophosphate+Kit+Injection%22+AND+company_name%3A%22Sun+Pharmaceutical+Industries%2C+Inc.%22+AND+package_ndc%3A%2245567-0060-2%22", "status_counts": { "Current": 3 }, "top_reasons": [ { "count": 3, "reason": "Shortage of an active ingredient" } ] } ], "top_priority": [ { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "61703-339-18", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)", "priority": "high", "related_info": "Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: September 2026", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-339-18%22", "source_record_key": "c644bbfd3ae85de6b311a592a220b0c02e98d700", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "61703-262-05", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)", "priority": "high", "related_info": "Next Delivery and Estimated Recovery: June 2026", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-262-05%22", "source_record_key": "afd8a65ea59142784dec5b27c1c5a485676e217a", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "61703-339-50", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)", "priority": "high", "related_info": "Next Delivery: April 2026; Estimated Recovery: September 2026", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-339-50%22", "source_record_key": "65e317bf6d11f4978c5158308d8916da4ee60f31", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Methotrexate Sodium Injection", "initial_posting_date": "2023-03-13", "package_ndc": "63323-123-10", "presentation": "Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)", "priority": "high", "related_info": "Check wholesaler for inventory", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Methotrexate+Sodium+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-123-10%22", "source_record_key": "37471f80cbc2aec8bdbb3e37b319c5dc8dc8da2e", "status": "Current", "therapeutic_category": "Rheumatology; Oncology", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Dexamethasone Sodium Phosphate Injection", "initial_posting_date": "2019-02-08", "package_ndc": "63323-516-10", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)", "priority": "high", "related_info": "Next release May 2026. Check wholesalers for inventory.", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexamethasone+Sodium+Phosphate+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-516-10%22", "source_record_key": "b2c8d4c81f09645c8946429de108920fbe4f76d0", "status": "Current", "therapeutic_category": "Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology", "update_date": "2026-04-23", "update_type": "Revised" }, { "company_name": "Gland Pharma Limited", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "54288-166-01", "presentation": "Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)", "priority": "high", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2254288-166-01%22", "source_record_key": "30533240f2ed29767dae4c9deeea4e6af2f5bcff", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-24", "update_type": "Revised" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "61703-339-22", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)", "priority": "high", "related_info": "Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: September 2026", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-339-22%22", "source_record_key": "8ff2a933d8afc2ece803c2d1ddaa03cd6ddc6091", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Gland Pharma Limited", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "54288-165-01", "presentation": "Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)", "priority": "high", "related_info": "Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2254288-165-01%22", "source_record_key": "b041fea115eb6929b559a12833acf3614008b1b3", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-24", "update_type": "Revised" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "61703-600-05", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)", "priority": "high", "related_info": "Next Delivery and Estimated Recovery: June 2026", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-600-05%22", "source_record_key": "6a7e358a5c66a969e7da4647f2c820e14ed0555d", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Dexamethasone Sodium Phosphate Injection", "initial_posting_date": "2019-02-08", "package_ndc": "76045-106-10", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexamethasone+Sodium+Phosphate+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2276045-106-10%22", "source_record_key": "44fed3f5b7a8bb796d4a12e76e18f67208f289fa", "status": "Current", "therapeutic_category": "Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "61703-339-56", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)", "priority": "high", "related_info": "Next Delivery: April 2026; Estimated Recovery: September 2026", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-339-56%22", "source_record_key": "509e3878061f75548677104c3df59f2172a8406e", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Gland Pharma Limited", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "54288-167-01", "presentation": "Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)", "priority": "high", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "score": 80, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2254288-167-01%22", "source_record_key": "2091553aac325d88c9925e872ae82c25986c765c", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-24", "update_type": "Revised" }, { "company_name": "Sagent Pharmaceuticals", "contact_info": "866-625-1618", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Rocuronium Bromide Injection", "initial_posting_date": "2023-02-15", "package_ndc": "25021-687-05", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)", "priority": "high", "related_info": "Estimated recovery: June 2026", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rocuronium+Bromide+Injection%22+AND+company_name%3A%22Sagent+Pharmaceuticals%22+AND+package_ndc%3A%2225021-687-05%22", "source_record_key": "35cb7dc8fc16982fb6d2c4230a882759db4f581f", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "63323-492-31", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-492-31%22", "source_record_key": "5235d925d05f9d01a66d7ec443179503763ae0f0", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Ropivacaine Hydrochloride Injection", "initial_posting_date": "2018-03-23", "package_ndc": "63323-285-10", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Ropivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-285-10%22", "source_record_key": "3954ac1b879c58d744d1859cb2fd4322e5675a16", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "63323-493-97", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-493-97%22", "source_record_key": "04387f479ca5e3cfbedb619b06c33d5b4a3986b2", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "63323-485-57", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)", "priority": "high", "related_info": "Check wholesalers for inventory", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-485-57%22", "source_record_key": "e6954e4c62f1764174d2f3b10cd53f757509b6ec", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "63323-493-91", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-493-91%22", "source_record_key": "4326d582900299e75b53c483bfc224e0e3cda5e0", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Ropivacaine Hydrochloride Injection", "initial_posting_date": "2018-03-23", "package_ndc": "63323-287-20", "presentation": "Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Ropivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-287-20%22", "source_record_key": "74948485f90e27b60fd6d461784cd9ae03407bd5", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "63323-484-57", "presentation": "Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-484-57%22", "source_record_key": "9b8f84e3ff798c3c702852b1da724b32fe28bb50", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Dexmedetomidine Hydrochloride Injection", "initial_posting_date": "2020-04-10", "package_ndc": "63323-421-02", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexmedetomidine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-421-02%22", "source_record_key": "350f97c2a2cc364a341a3e321cf5cf9aa0191ac8", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Midazolam Hydrochloride Injection", "initial_posting_date": "2020-04-02", "package_ndc": "0409-2305-05", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)", "priority": "high", "related_info": "Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: June 2026", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Midazolam+Hydrochloride+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-2305-05%22", "source_record_key": "6d070a705a554e7fce1bf974469e2ef63058bfec", "status": "Current", "therapeutic_category": "Anesthesia; Neurology", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Midazolam Hydrochloride Injection", "initial_posting_date": "2020-04-02", "package_ndc": "76045-211-20", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)", "priority": "high", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Midazolam+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2276045-211-20%22", "source_record_key": "465da93a8d4c901ddd8daac3089d6ca73e71e9fc", "status": "Current", "therapeutic_category": "Anesthesia; Neurology", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Gland Pharma Limited", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "54288-164-01", "presentation": "Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)", "priority": "high", "related_info": "Discontinued; Distributed by BPI Labs, LLC", "score": 78, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2254288-164-01%22", "source_record_key": "8307fd4415ccb92e2a867634d7b383cac6151e67", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-24", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Ropivacaine Hydrochloride Injection", "initial_posting_date": "2018-03-23", "package_ndc": "63323-285-13", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)", "priority": "high", "related_info": "Next release May 2026. Check wholesalers for inventory.", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Ropivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-285-13%22", "source_record_key": "0c952d2fac78a9ff2ee982722c1a4a0ba42dcba8", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-23", "update_type": "Revised" }, { "company_name": "Pfizer Inc.", "contact_info": "800-533-4535", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Clindamycin Phosphate Injection", "initial_posting_date": "2023-03-21", "package_ndc": "0009-0870-26", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)", "priority": "high", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: December 2028", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Clindamycin+Phosphate+Injection%22+AND+company_name%3A%22Pfizer+Inc.%22+AND+package_ndc%3A%220009-0870-26%22", "source_record_key": "dffcfbd15679d896a483899d4fcda32a33261230", "status": "Current", "therapeutic_category": "Anti-Infective", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Midazolam Hydrochloride Injection", "initial_posting_date": "2020-04-02", "package_ndc": "63323-412-10", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Midazolam+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-412-10%22", "source_record_key": "c44cda4b9a6750fe12a30aa5a912ea75b4ce2ffb", "status": "Current", "therapeutic_category": "Anesthesia; Neurology", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "63323-496-97", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-496-97%22", "source_record_key": "788ac8954a0a25faaca7696648d51cbccc2bf978", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Bupivacaine Hydrochloride Injection", "initial_posting_date": "2018-02-20", "package_ndc": "63323-464-31", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)", "priority": "high", "related_info": "Expected recovery: TBD", "score": 78, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bupivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-464-31%22", "source_record_key": "095f5b0bb9c08ca7eebdda4a8c6c0f1beb852639", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Accord Healthcare Inc.", "contact_info": "866-941-7875, option 2", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Methotrexate Sodium Injection", "initial_posting_date": "2023-03-13", "package_ndc": "16729-277-30", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)", "priority": "high", "related_info": "Estimated recovery: 30 days", "score": 77, "shortage_reason": "Shortage of an active ingredient", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Methotrexate+Sodium+Injection%22+AND+company_name%3A%22Accord+Healthcare+Inc.%22+AND+package_ndc%3A%2216729-277-30%22", "source_record_key": "77b5f8b4f3c49d139d0d3b0d61e870d20fe99e61", "status": "Current", "therapeutic_category": "Rheumatology; Oncology", "update_date": "2026-04-15", "update_type": "Revised" }, { "company_name": "Sagent Pharmaceuticals", "contact_info": "866-625-1618", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Bumetanide Injection", "initial_posting_date": "2018-01-31", "package_ndc": "25021-321-10", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)", "priority": "high", "related_info": "Product in transit, expected to arrive last week of April 2026", "score": 76, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bumetanide+Injection%22+AND+company_name%3A%22Sagent+Pharmaceuticals%22+AND+package_ndc%3A%2225021-321-10%22", "source_record_key": "fddf44d94a7a5b4419e44b8a338bed46aca6f9e8", "status": "Current", "therapeutic_category": "Cardiovascular", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Atropine Sulfate Injection", "initial_posting_date": "2012-01-01", "package_ndc": "0409-4910-34", "presentation": "Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\"", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug", "score": 76, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Atropine+Sulfate+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-4910-34%22", "source_record_key": "e50616e2631b37dda70f568da821a90101362461:001", "status": "Current", "therapeutic_category": "Anesthesia; Neurology; Pediatric", "update_date": "2026-04-22", "update_type": "Reverified" }, { "company_name": "Sagent Pharmaceuticals", "contact_info": "866-625-1618", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Bumetanide Injection", "initial_posting_date": "2018-01-31", "package_ndc": "25021-321-04", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)", "priority": "high", "related_info": "Product in transit, expected to arrive last week of April 2026", "score": 76, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bumetanide+Injection%22+AND+company_name%3A%22Sagent+Pharmaceuticals%22+AND+package_ndc%3A%2225021-321-04%22", "source_record_key": "c8147afc34aada650a3165a15ad9e87773589924", "status": "Current", "therapeutic_category": "Cardiovascular", "update_date": "2026-04-23", "update_type": "Reverified" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "0409-4904-34", "presentation": "Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug", "score": 76, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-4904-34%22", "source_record_key": "87cdf169f45b2038424bb4c01ccd4f4f40370db7", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-22", "update_type": "Reverified" }, { "company_name": "Pfizer Inc.", "contact_info": "800-533-4535", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Clindamycin Phosphate Injection", "initial_posting_date": "2023-03-21", "package_ndc": "0009-4073-04", "presentation": "Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)", "priority": "high", "related_info": "Estimated recovery: TBD", "score": 76, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Clindamycin+Phosphate+Injection%22+AND+company_name%3A%22Pfizer+Inc.%22+AND+package_ndc%3A%220009-4073-04%22", "source_record_key": "a8c5ebe73b00c682318f4d4d773ea47967719b7b", "status": "Current", "therapeutic_category": "Anti-Infective", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "0409-4903-34", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug", "score": 76, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-4903-34%22", "source_record_key": "03234dc70ce4ca040fa7d6148b1f9106890e22f0", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-22", "update_type": "Reverified" }, { "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Atropine Sulfate Injection", "initial_posting_date": "2012-01-01", "package_ndc": "0409-4911-34", "presentation": "Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\"", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug", "score": 76, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Atropine+Sulfate+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-4911-34%22", "source_record_key": "869d02e3ad55278334692b8a72304eaebc22c521:002", "status": "Current", "therapeutic_category": "Anesthesia; Neurology; Pediatric", "update_date": "2026-04-22", "update_type": "Reverified" }, { "company_name": "Pfizer Inc.", "contact_info": "800-533-4535", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Clindamycin Phosphate Injection", "initial_posting_date": "2023-03-21", "package_ndc": "0009-3051-02", "presentation": "Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)", "priority": "high", "related_info": "Estimated recovery: TBD", "score": 76, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Clindamycin+Phosphate+Injection%22+AND+company_name%3A%22Pfizer+Inc.%22+AND+package_ndc%3A%220009-3051-02%22", "source_record_key": "056a0d99fd237eb34c3ceb556d15bd05614923aa", "status": "Current", "therapeutic_category": "Anti-Infective", "update_date": "2026-04-22", "update_type": "Revised" }, { "company_name": "Teyro Labs", "contact_info": "Apotex Inc.: 800-706-5575", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "60505-6282-3", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug.", "score": 75, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Teyro+Labs%22+AND+package_ndc%3A%2260505-6282-3%22", "source_record_key": "d46fabb84b9b8f84009bec8ae5c6d865e5418e13", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-20", "update_type": "Reverified" }, { "company_name": "Teyro Labs", "contact_info": "Apotex Inc.: 800-706-5575", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "60505-6282-7", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug.", "score": 75, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Teyro+Labs%22+AND+package_ndc%3A%2260505-6282-7%22", "source_record_key": "16da0f2f536a61eb6673fa54f0c4b5e55915415a", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-20", "update_type": "Revised" }, { "company_name": "XGen Pharmaceuticals DJB, Inc.", "contact_info": "866-390-4411", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Rocuronium Bromide Injection", "initial_posting_date": "2023-02-15", "package_ndc": "39822-4200-2", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)", "priority": "high", "related_info": "", "score": 75, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rocuronium+Bromide+Injection%22+AND+company_name%3A%22XGen+Pharmaceuticals+DJB%2C+Inc.%22+AND+package_ndc%3A%2239822-4200-2%22", "source_record_key": "e2f40b32cf363ebc503f07880ba1284272fa359a", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-21", "update_type": "Reverified" }, { "company_name": "XGen Pharmaceuticals DJB, Inc.", "contact_info": "866-390-4411", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Rocuronium Bromide Injection", "initial_posting_date": "2023-02-15", "package_ndc": "39822-4200-6", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)", "priority": "high", "related_info": "", "score": 75, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rocuronium+Bromide+Injection%22+AND+company_name%3A%22XGen+Pharmaceuticals+DJB%2C+Inc.%22+AND+package_ndc%3A%2239822-4200-6%22", "source_record_key": "302a70102535e7d7563c7ccfd2605ed5dfd5a1a9", "status": "Current", "therapeutic_category": "Anesthesia", "update_date": "2026-04-21", "update_type": "Revised" }, { "company_name": "Teyro Labs", "contact_info": "Apotex Inc.: 800-706-5575", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "60505-6282-1", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug.", "score": 75, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Teyro+Labs%22+AND+package_ndc%3A%2260505-6282-1%22", "source_record_key": "d6be120e29b207ebbdb7d868f9d8e8cc0ef2769e", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-20", "update_type": "Reverified" }, { "company_name": "Teyro Labs", "contact_info": "Apotex Inc.: 800-706-5575", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Carboplatin Injection", "initial_posting_date": "2023-04-28", "package_ndc": "60505-6282-6", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug.", "score": 75, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Teyro+Labs%22+AND+package_ndc%3A%2260505-6282-6%22", "source_record_key": "e3ce14f4220189b0d32b86c0c3e9bf444627713a", "status": "Current", "therapeutic_category": "Oncology", "update_date": "2026-04-20", "update_type": "Reverified" }, { "company_name": "Amphastar Pharmaceuticals, Inc.", "contact_info": "800-423-4136", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Lidocaine Hydrochloride Injection", "initial_posting_date": "2012-02-22", "package_ndc": "76329-3390-1", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)", "priority": "high", "related_info": "old NDC 0548-3390-00", "score": 75, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Amphastar+Pharmaceuticals%2C+Inc.%22+AND+package_ndc%3A%2276329-3390-1%22", "source_record_key": "764dd92458694b34ed3a816dfb1064fd73f89ab0", "status": "Current", "therapeutic_category": "Anesthesia; Pediatric", "update_date": "2026-04-20", "update_type": "Revised" }, { "company_name": "Gland Pharma Limited", "contact_info": "866-625-1618", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Furosemide Injection", "initial_posting_date": "2020-04-07", "package_ndc": "25021-311-02", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)", "priority": "high", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "score": 74, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Furosemide+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2225021-311-02%22", "source_record_key": "cbac69de9e693e968561723f6b8d511982b9d2da", "status": "Current", "therapeutic_category": "Cardiovascular", "update_date": "2026-04-24", "update_type": "Revised" }, { "company_name": "Gland Pharma Limited", "contact_info": "866-625-1918", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Furosemide Injection", "initial_posting_date": "2020-04-07", "package_ndc": "25021-311-10", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)", "priority": "high", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "score": 74, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Furosemide+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2225021-311-10%22", "source_record_key": "fae5b91762fc3f088533de04ac4fd53e53902cb1", "status": "Current", "therapeutic_category": "Cardiovascular", "update_date": "2026-04-24", "update_type": "Revised" }, { "company_name": "Fresenius Kabi USA, LLC", "contact_info": "888-386-1300", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Heparin Sodium Injection", "initial_posting_date": "2017-11-14", "package_ndc": "63323-519-10", "presentation": "Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)", "priority": "high", "related_info": "Next release May 2026. Check wholesalers for inventory.", "score": 74, "shortage_reason": "Demand increase for the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Heparin+Sodium+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-519-10%22", "source_record_key": "d73d372cc2595ae7360baa1e3241ba76a3f74714", "status": "Current", "therapeutic_category": "Hematology", "update_date": "2026-04-23", "update_type": "Revised" }, { "company_name": "Gland Pharma Limited", "contact_info": "866-625-1618", "discontinued_date": "", "dosage_form": "Injection", "generic_name": "Furosemide Injection", "initial_posting_date": "2020-04-07", "package_ndc": "25021-311-04", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)", "priority": "high", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "score": 74, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Furosemide+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2225021-311-04%22", "source_record_key": "5bbcabe84d6f205fc3f9d7a37822714fa202f9f1", "status": "Current", "therapeutic_category": "Cardiovascular", "update_date": "2026-04-24", "update_type": "Revised" }, { "company_name": "Epic Pharma, LLC", "contact_info": "(718) 276-8600 ext. 3", "discontinued_date": "", "dosage_form": "Capsule", "generic_name": "Rifampin Capsule", "initial_posting_date": "2021-12-22", "package_ndc": "42806-799-01", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-01)", "priority": "high", "related_info": "Discontinuation of the manufacture of the drug.", "score": 73, "shortage_reason": "Discontinuation of the manufacture of the drug", "source_query_url": "https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rifampin+Capsule%22+AND+company_name%3A%22Epic+Pharma%2C+LLC%22+AND+package_ndc%3A%2242806-799-01%22", "source_record_key": "c627dd7ca53fff58aaff72ba25d7da8c642c7978", "status": "Current", "therapeutic_category": "Anti-Infective", "update_date": "2026-04-20", "update_type": "Reverified" } ], "total_records": 1683 }